Redrawing the biopharma map: India’s rise in the biosimilars era Dr Cyrus Karkaria Mar 10, 2026 For India’s biopharma sector, 2025 stood out as an inflection point. The approval of 146 recombinant biosimilar therapeutic…
We are cost-competitive and aligned with global ESG framework demands Viveka Roychowdhury Jan 8, 2026 The biologics sector is very dependent on single-use products and containment solutions. For example, the COVID pandemic exposed…
